Scilex Holding Company (SCLXW) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Palo Alto, CA, 미국. 현재 CEO는 Henry H. Ji.
SCLXW 을(를) 보유 IPO 날짜 2021-03-05, 115 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $934.19K.
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
